宫颈癌免疫治疗研究进展
Research progress on cervical cancer immunotherapy
张卉迎 1王云飞2
作者信息
- 1. 济宁医学院临床医学院,济宁 272013
- 2. 济宁医学院附属医院,济宁 272029
- 折叠
摘要
在女性恶性肿瘤中,宫颈癌是一种较为典型的妇科肿瘤.宫颈癌在早期往往没有明显的症状和体征,而到了中晚期患者通常需要通过手术、放疗和化疗等方法进行治疗,但预后通常不佳.随着分子生物学及免疫学的迅速发展,人们对肿瘤发病机制有了更深入地了解,免疫治疗成为恶性肿瘤的治疗新方法,也成为宫颈癌治疗的研究热点.本文就简要综述宫颈癌免疫治疗的最新研究进展,包括就 HPV疫苗、过继性 T细胞疗法(TILs、TCR-T、CAR-T)、肿瘤免疫检查点抑制疗法(PD-1/PD-L1 通路抑制剂、CTLA-4检查点抑制剂)及多种免疫治疗联合治疗宫颈癌的策略.
Abstract
Among women's malignant tumors,cervical cancer is a more typical gynecological tumor.There are no obvious symptoms and signs of cervical cancer in the early stage.Patients in the middle and late stages are treated by sur-gery,radiotherapy and chemotherapy,and the prognosis is relatively poor.The rapid development of molecular biology and immunology has discovered the pathogenesis of tumors.Immunotherapy has become a new method of treating various malignant tumors and a research hotspot for cervical cancer treatment.This article summarizes the research progress of HPV vaccine,secondary T cell therapy(TILs,TCR-T,CAR-T),tumor immune checkpoint inhibition therapy(PD-1/PD-L1 pathway inhibitor,CTLA-4 checkpoint inhibitor)and multiple immunotherapy combined treatment of cervical cancer.
关键词
宫颈癌/免疫治疗/HPV疫苗/过继性T细胞疗法/肿瘤免疫检查点抑制疗法/联合治疗Key words
Cervical cancer/Immunotherapy/HPV vaccine/Adoptive T-cell therapy/Tumor immune checkpoint inhibition therapy/Combined treatment引用本文复制引用
出版年
2024
NETL
NSTL
万方数据